J. Basso

Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial

M. Cairo, C. Moorthy, S. Voss, 2022, Journal for ImmunoTherapy of Cancer.

Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

M. Cairo, S. Voss, J. Hochberg, 2020 .

Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B

M. Cairo, L. Baxter‐Lowe, B. Mehta, 2022, Leukemia & lymphoma.

Phase II results of mitoxantrone in combination with clofarabine in children with relapsed/refractory acute leukemia.

M. Borowitz, M. Loken, M. Cairo, 2019, Journal of Clinical Oncology.